RVL Pharmaceuticals plc

OTCPK:RVLP.Q Rapporto sulle azioni

Cap. di mercato: US$111.0

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RVL Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

RVL Pharmaceuticals' Il CEO è Brian Markison, nominato in Jan2016, ha un mandato di 8.58 anni. possiede direttamente 2.1% delle azioni della società, per un valore di $ 2.33. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.6 anni e 5.2 anni.

Informazioni chiave

Brian Markison

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO8.6yrs
Proprietà del CEO2.1%
Durata media del management8.6yrs
Durata media del Consiglio di amministrazione5.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt Extensively

May 05
These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt Extensively

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian Markison rispetto agli utili di RVL Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$525kUS$525k

-US$52m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$1mUS$665k

-US$83m

Sep 30 2021n/an/a

-US$115m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$82m

Dec 31 2020US$4mUS$716k

-US$89m

Sep 30 2020n/an/a

-US$64m

Jun 30 2020n/an/a

-US$178m

Mar 31 2020n/an/a

-US$285m

Dec 31 2019US$4mUS$683k

-US$271m

Sep 30 2019n/an/a

-US$351m

Jun 30 2019n/an/a

-US$243m

Mar 31 2019n/an/a

-US$112m

Dec 31 2018US$1mUS$633k

-US$110m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$10m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$1mUS$613k

-US$41m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Brian sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Brian Markison (65 yo)

8.6yrs

Mandato

US$525,000

Compensazione

Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Brian Markison
Chairman8.6yrsUS$525.00k2.1%
$ 2.3
James Schaub
Executive VP & COO8.6yrsUS$367.20k0.45%
$ 0.5
Christopher Klein
General Counsel10.7yrsUS$367.20k0.15%
$ 0.2
Michael DePetris
Principal Accounting Officer2.3yrsNessun datoNessun dato
Jarret Miller
Executive Vice President of Human Resources8.6yrsNessun datoNessun dato
Scott Schroppe
Secretaryno dataNessun datoNessun dato

8.6yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di RVLP.Q è esperto e expertise (durata media dell'incarico 8.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Brian Markison
Chairman8.6yrsUS$525.00k2.1%
$ 2.3
Gregory Cowan
Independent Director5.6yrsUS$234.00k0.045%
$ 0.05
Alisa Lask
Independent Director2yrsUS$159.94k0.020%
$ 0.02
Michael DeBiasi
Independent Director4.8yrsUS$309.10kNessun dato

5.2yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RVLP.Q sono considerati esperti (durata media dell'incarico 5.2 anni).